← Back to Home

Looking Only at DNA May Miss Clues for Lung Cancer Treatment: RNA Testing Detects MET Exon Skipping

A real-world study identified 171 variants involving the MET exon 14 splice region, showing that abnormalities in gene sequences may not be easy to interpret; adding RNA confirmation can recover, for some patients, biomarkers that determine eligibility for targeted therapy.

By SURL BioNews

For some patients with non-small cell lung cancer, a seemingly subtle genetic change—one that may even be classified as harmless—can determine whether they are eligible for MET-targeted therapy. A large real-world study published in *The Journal of Molecular Diagnostics* found that if the testing process reads only DNA, some abnormalities that cause MET exon 14 skipping may be missed or misclassified; RNA can directly reveal the result after splicing, providing critical supporting evidence.

MET exon 14 skipping occurs in approximately 3% to 4% of non-small cell lung cancers. Such changes affect the regulation of the MET protein and have therefore become an important biomarker for treatment selection. The challenge is that skipping is not caused by a single hotspot mutation. Instead, the responsible alterations may be distributed across a broader splice region and can be far more complex than the point mutations familiar from conventional genetic testing.

The research team identified 171 distinct variants affecting the MET exon 14 splice region from routine clinical testing data and used RNA analysis to confirm that more than 100 variant types did indeed cause exon skipping. The results connected variants in DNA that “may affect splicing” to their actual consequences at the RNA level, while also highlighting that variant location or existing annotations alone may not be sufficient to determine clinical significance.

Particularly challenging cases included genomic deletions spanning larger regions and a synonymous variant that appeared not to change the amino acid sequence but disrupted splicing. DNA testing may miss or misclassify these events because of probe coverage, bioinformatics filtering rules, or variant interpretation methods; RNA testing can directly confirm whether the mature transcript lacks exon 14. However, RNA quality is easily affected by specimen preservation and tissue condition, so RNA is better suited as complementary evidence than as a replacement for DNA analysis in every setting.

Multinational external quality assessments also showed a gap between specimen types: the overall success rate for tissue testing reached 98%, indicating that properly validated methods can be performed consistently across laboratories. Liquid biopsy remains more difficult. Although its success rate increased from 37.5% in 2022 to 63% in 2024, factors such as low circulating tumor DNA levels and complex variant structures may still hinder detection.

This study did not compare whether different testing strategies improve patient survival, nor did it demonstrate that every negative result must be followed by additional RNA testing. Its central message is more about calibrating the diagnostic workflow: when DNA results are unclear, a variant is located in a splice region, or clinical and pathological features remain suspicious, adding RNA confirmation when specimen conditions permit may reduce the risk that patients miss an evaluation for MET-targeted therapy because of technical blind spots.

References

  1. Elsevier
  2. News-Medical.Net